March 22, 2022 02:14 PM EDT
Pharma
Law

Gener­ic drug in­dus­try calls on FTC to dig in­to monop­sony pow­er among buy­ers, PBMs

Zachary Brennan

Senior Editor

The gener­ic drug in­dus­try group is call­ing on the Fed­er­al Trade Com­mis­sion to crack down on monop­sony pow­er — or un­due mar­ket con­trol — ex­er­cised by drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times